^
    Back
    Association details:
    Biomarker:HER-2 fusion
    Cancer:Non Small Cell Lung Cancer
    Drug:Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Am J Clin Oncol
    Title:

    Real-world large-scale study of ERBB2 gene fusions and its response to afatinib in Chinese non-small cell lung cancer (NSCLC): A multicenter study.

    Excerpt:
    Patients with advanced ERBB2 fusion NSCLC showed a good outcome of afatinib…
    DOI:
    10.1200/JCO.2019.37.15_suppl.e13002